semaglutide menopause and Weight Loss: What Women Should Know Semaglutide and Menopause: Does It

Use comparisons to prepare better questions, not to replace medical guidance

Risk factors that may prompt additional consideration include: Active gastrointestinal symptoms (nausea, vomiting, abdominal pain) Recent dose increases or being in the dose-escalation phase Higher doses of semaglutide Known gastroparesis or other conditions affecting gastric emptying Obesity with GERD or hiatal hernia Based on the 2024 multi-society guidance, most patients can continue GLP-1 receptor agonists before elective procedures with appropriate risk assessment and mitigation strategies, rather than automatic postponement

1,2 Given that GLP-1 is a large protein, analogs are primarily administered via subcutaneous injection, with the exception of oral semaglutide 7 mg or 14 mg (Rybelsus, Novo Nordisk)

As a competitive inhibitor of xCT, it promotes GSH consumption while inhibiting the expression of the antioxidant H2S-producing enzyme cystathionine-synthase (CBS) to achieve oxidative stress toxicity

Additionally, other low molecular weight sulfated polysaccharides, such as amylopectin sulfate and DSS, have been shown to have similar toxicological effects as PGN

Chick chorioallantoic membrane assays have confirmed pro-angiogenic activity, with GHK-Cu treatment producing 40-60% increases in vascular density within developing membranes